Primary Immunodeficiency Disease Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases
Condition: Primary Immune Deficiency Disorder Intervention: Drug: CUTAQUIG Sponsor: Octapharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 6, 2019 Category: Research Source Type: clinical trials
Clinical phase 3 study to monitor the safety, tolerability, and efficacy of subcutaneous human immunoglobulin (cutaquig ®) administered at modified dosing regimens in patients with primary immunodeficiency diseases
Condition: Primary Immune Deficiency Disorder Intervention: Drug: CUTAQUIG Sponsor: Octapharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 6, 2019 Category: Research Source Type: clinical trials
Study to Monitor the Safety, Tolerability and Efficacy of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Primary Immunodeficiency Diseases, Including (But Not Limited to) Those Who Have Completed the SCGAM-01 Trial
Condition: Primary Immunodeficiency Intervention: Drug: Octanorm 16.5% Sponsor: Octapharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2019 Category: Research Source Type: clinical trials
